Quality of life and muscle strength improvement in an amyotrophic lateral sclerosis patient after nutraceuticals*

Jozélio  Freire de Carvalho; João Ricardo  Yamasita; Леонид Чурилов

doi:10.21638/spbu11.2020.308

Авторы

Jozélio Freire de Carvalho Institute for Health Sciences, Federal University of Bahia, Rua Augusto Viana, Palácio da Reitoria, Canela, Salvador, 40110-909, Brazil
João Ricardo Yamasita Instituto de Medicina Consciente, Av. João Paulo II, 1110 Jardim Panorama, Foz do Iguaçu-PR, 85856-110, Brazil
Леонид Чурилов St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation

DOI:

https://doi.org/10.21638/spbu11.2020.308

Аннотация

The objective of the article was to describe a patient with amyotrophic lateral sclerosis (ALS) treated with nutraceuticals who had a better quality of life and improved muscle strength. A 65-year-old male patient with a past medical history of gout was diagnosed with amyotrophic lateral sclerosis in 2016. He received intravenous immunoglobulin and prednisone, but no improvement was observed. In 2018, he was diagnosed with multiple myeloma, submitted to a bone marrow transplant, and initiated riluzole. After 2 months, he came to our private clinic; he could not walk anymore and used outpatient nasal ventilator equipment. Beck anxiety inventory (BAI) was 20 [normal range (nr): < 8], Beck depression inventory (BDI) was 12 (nr: < 10), Bristol stool form scale (BSTS) was 5 (nr: 3–4), and there were 7 symptoms of dysbiosis. Analogic visual scale (Lickert scale) for well-being was 5.0. We suspended the colchicine, added vitamin D3, creatine, vitamin C, N-acetyl cysteine, 5-hydroxytryptamine, B1, and B6 vitamins. Dysbiosis was also treated. After 2 months, he returned feeling much better, BAI and BDI reduced BDI to 11, and BSFS normalized. Following this evaluation, a nutraceutical prescription was added: methylfolate, zinc, magnesium, green tea extract, Ginkgo biloba, lipoic acid, pyrroloquinoline quinone, vitamin E, coenzyme Q10, and resveratrol. After 7 months, he was feeling very well; BAI and BDI were normal, he gained weight. He felt a marked improvement in his muscle strength, and he gained again the capacity of eating alone, his quality of life improved, and AVS well-being was 8.0. This report illustrates a demonstrative case of a patient with ALS treated with nutraceuticals and improved his quality of life and muscle strength. It may be an alternative therapeutic option for such patients.

Ключевые слова:

amyotrophic lateral sclerosis, neurological disorders, lower neuron disease, immunity, vitamin D, nutraceuticals, supplements

Скачивания

Данные скачивания пока недоступны.

Библиографические ссылки

References

Ralli M., Lambiase A., Artico M., de Vincentiis M., Greco A. Amyotrophic Lateral Sclerosis: Autoimmune Pathogenic Mechanisms, Clinical Features, and Therapeutic Perspectives. Isr. Med. Assoc. J. 2019, vol. 21, no. 7, pp. 438–443.

Pagani M. R., Gonzalez L. E., Uchitel O. D. Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurol. Res Int., 2011, 497080. https://doi.org/10.1155/2011/497080.

Momtaz S., Memariani Z., El-Senduny F. F., Sanadgol N., Golab F., Katebi M., Abdolghaffari A. H., Farzaei M. H., Abdollahi M. Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases. Front. Physiol., 2020, vol. 11, p. 361. https://doi.org/10.3389/fphys.2020.00361.

del Aguila M. A., Longstreth W. T. Jr., McGuire V., Koepsell T. D., van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology, 2003, vol. 60, pp. 813–819.

Miller R. G., Mitchell J. D., Moore D. H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev., 2012, vol. 3, CD001447. https://doi.org/10.1002/14651858.CD001447.pub3.

Brudon F., Bady B., Chauplannaz G., Joyeux O., Vial C., Chan V., Guillaud-Barbaret C., Chazot G. Syndromes cliniques de SLA au cours des gammapathies: aspects cliniques, électrophysiologiques et histoimmunologiques. Rev. Electroencephalogr.Neurophysiol. Clin., 1986, vol. 15, no. 4, pp. 369–373. https://doi.org/10.1016/s0370-4475(86)80044-2.

Masi M. C., Gironelli L., Bonuccelli U., Cei G., Meucci G., Giraldi C. Sclerosi laterale amiotrofica in corso di mieloma multiplo. Riv. Neurol., 1990, vol. 60, no. 5, pp. 167–170.

Vannucci P., Castiglioni M., Filidei M., Riccioni N. Sclerosi laterale amiotrofica in un paziente con macroglobulinemia di Waldenstrom. Minerva Med., 1997, vol. 88, no. 4, pp. 167–170.

Defuentes G., Lecoules S. ., Desramé J, Béchade D., Coutant G., Flocard F., Algayres J. P. Syndrome de sclérose latérale amyotrophique au cours d’un myélome multiple. Rev. Med. Interne., 2004, vol. 25, no. 10, pp. 766–768.

Koc F., Paydas S., Yerdelen D., Demirkiran M. Motor neuron disease associated with multiple myeloma. Int. J. Neurosci. 2008, vol. 118, no. 3, pp. 337–341. https://doi.org/10.1080/00207450701242644.

Juntas-Morales R., Pageot N., Marin G., Dupuy A. M., Alphandery S., Labar L., Esselin F., Picot M. C., Camu W. Low 25OH Vitamin D Blood Levels Are Independently Associated with Higher Amyotrophic Lateral Sclerosis Severity Scores: Results From a Prospective Study. Front. Neurol., 2020, vol. 11, p. 363. https://doi.org/10.3389/fneur.2020.00363.

Charoenngam N., Holick M. F. Immunologic Effects of Vitamin D on Human Health and Disease. Nutrients, 2020, vol. 12, no. 7, p. 2097. https://doi.org/10.3390/nu12072097.

Karam C., Barrett M. J., Imperato T., MacGowan D. J., Scelsa S. Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. J. Clin. Neurosci., 2013, vol. 20, no. 11, pp. 1550–1553. https://doi.org/10.1016/j.jocn.2013.01.011.

Mazzini L., Balzarini C., Colombo R., Mora G., Pastore I., De Ambrogio R., Caligari M. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. J. Neurol. Sci., 2001, vol. 191, no. 1–2, pp. 139–144. https://doi.org/10.1016/s0022-510x(01)00611-6.

Ascherio A., Weisskopf M. G., O’reilly E. J., Jacobs E. J., McCullough M. L., Calle E. E., Cudkowicz M., Thun M. J. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann. Neurol., 2005, vol. 57, no. 1,pp. 104–110. https://doi.org/10.1002/ana.20316.

Zoccolella S., Simone I. L., Lamberti P., Samarelli V., Tortelli R., Serlenga L., Logroscino G. Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology, 2008, vol. 70, no. 3, pp. 222–225. https://doi.org/10.1212/01.wnl.0000297193.53986.6f.

Kaji R., Imai T., Iwasaki Y., Okamoto K., Nakagawa M., Ohashi Y., Takase T., Hanada T., Shimizu H., Tashiro K., Kuzuhara S. Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a longterm phase II/III randomised controlled study. J. Neurol. Neurosurg. Psychiatry, 2019, vol. 90, no. 4, pp. 451–457.

Shaw K., Turner J., Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst. Rev., 2002, vol. 1, CD003198. https://doi.org/10.1002/14651858.CD003198.

Moling O., Di Summa A., Capone L., Stuefer J., Piccin A., Porzia A., Capozzi A., Sorice M., Binazzi R., Gandini L., Rimenti G., Mian P. Increased IL-17, a Pathogenic Link between Hepatosplenic Schistosomiasis and Amyotrophic Lateral Sclerosis: A Hypothesis. Case Reports Immunol., 2014, 804761.

Harvey W. T., Martz D. Motor neuron disease recovery associated with IV ceftriaxone and anti-Babesia therapy. Acta. Neurol. Scand., 2007, vol. 115, no. 2, pp. 129–131.

Shi T., Bian X., Yao Z., Wang Y., Gao W., Guo C. Quercetin improves gut dysbiosis in antibiotic-treated mice. Food Funct., 2020, vol. 11, no. 9, pp. 8003–8013. https://doi.org/10.1039/d0fo01439g.

Lyu Y., Wu L., Wang F., Shen X., Lin D. Carotenoid supplementation and retinoic acid in immunoglobulin A regulation of the gut microbiota dysbiosis. Exp. Biol. Med. (Maywood), 2018, vol. 243 (7), pp. 613–620. https://doi.org/10.1177/1535370218763760.

Jesse S., Thal D. R., Ludolph A. C. Thiamine deficiency in amyotrophic lateral sclerosis. J. Neurol. Neurosurg.Psychiatry, 2015, vol. 86, no. 10, pp. 1166–1168. https://doi.org/10.1136/jnnp-2014-309435.

McCarty M. F. High-dose pyridoxine as an ‘anti-stress’ strategy. Med. Hypotheses, 2000, vol. 54, no. 5, pp. 803–807. https://doi.org/10.1054/mehy.1999.0955.

De Souza M. C., Walker A. F., Robinson P. A., Bolland K. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related pre-menstrual symptoms: a randomized, double-blind, crossover study. J. Womens Health Gend. Based Med., 2000, vol. 9, no. 2, pp. 131–139. https://doi.org/10.1089/152460900318623.

Peters T. L., Beard J. D., Umbach D. M., Allen K., Keller J., Mariosa D., Sandler D. P., Schmidt S., Fang F., Ye W., Kamel F. Blood levels of trace metals and amyotrophic lateral sclerosis. Neurotoxicology, 2016,vol. 54, pp. 119–126. https://doi.org/10.1016/j.neuro.2016.03.022.

Mangelsdorf I., Walach H., Mutter J. Healing of Amyotrophic Lateral Sclerosis: A Case Report. Complement Med. Res., 2017, vol. 24, no. 3, pp. 175–181. https://doi.org/10.1159/000477397.

Ferrante R. J., Klein A. M., Dedeoglu A., Beal M. F. Therapeutic efficacy of EGb761 (Ginkgo biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. J. Mol. Neurosci., 2001, vol. 17, no. 1, pp. 89–96. https://doi.org/10.1385/jmn:17:1:89.

Mancuso M., Orsucci D., Calsolaro V., Choub A., Siciliano G. Coenzyme Q10 and Neurological Diseases. Pharmaceuticals (Basel), 2009, vol. 2, no. 3, pp. 134–149. https://doi.org/10.3390/ph203134.

Lemieszek M. K., Stepulak A., Sawa-Wejksza K., Czerwonka A., Ikonomidou C., Rzeski W. Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins. Anticancer Agents Med. Chem. 2018, vol. 18, no. 4, pp. 565–572. https://doi.org/10.2174/1871520618666180228152713.